LL LLY Eli Lilly and Company 로딩 중... : 애널리스트의 강세 및 약세 의견

Pfizer reports a Phase 1/2 trial design for its once-monthly GLP-1 and amylin combination is focused on tolerability, positioning it as a potential differentiated therapy. — A tolerable monthly combination could provide a significant convenience advantage over weekly rivals like Lilly's Zepbound.

Pfizer's PD-1/VEGF bispecific (4404) shows differentiated early data with high VEGFA affinity, potentially strengthening its lung cancer portfolio. — This could impact the competitive landscape in non-small cell lung cancer, challenging existing PD-1/angiogenesis combo therapies.

Acknowledges that the VESPR-3 trial design had no down-titration allowed, an unusual feature for obesity trials, suggesting the trial may have understated the drug's true tolerability/effectiveness profile. — Indicates the trial results may be conservative; allowing down-titration in Phase III could improve tolerability and thereby commercial success, competing directly with Lilly and Novo's products.